PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today announced that the U.S. Patent and Trademark Office has issued Patent Number 7,381,561 claiming the use of additional monoclonal antibodies for the prospective isolation of rare cells from human neural tissue, such as the Company’s HuCNS-SC® product candidate (purified human neural stem cells). The discovery and use of monoclonal antibodies to prospectively isolate rare cells, combined with its expertise in cell biology, has been a critical component of the Company’s successes to date.
